NeoStem CEO Dr. Robin Smith Interviewed on Clear Channel's "The Traders Network" Business Talk Radio

NEW YORK, NY--(Marketwired - Feb 19, 2014) - NeoStem, Inc. (NASDAQ: NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that Dr. Robin L. Smith, Chairman and CEO, was interviewed live on Clear Channel's "The Traders Network" hosted by Michael Yorba. This was Dr. Smith's second appearance on The Traders Network. In a two-part interview, Dr. Smith explained the Company's 2014 goals, 2013 achievements, and the increased visibility the Company is achieving in the cell therapy industry.

When asked why investors are interested in NeoStem, Dr. Smith explained how NeoStem has addressed three key risks that investors often assess before investing in a stem cell company; financing, patient enrollment and manufacturing capabilities. NeoStem has addressed these risks by, first, raising over $40 million this past October in its latest round of fundraising. Second, completing enrollment in its Phase 2 clinical trial testing AMR-001, its lead product candidate for cardiovascular disease, demonstrating management's skill in advancing product candidates through the clinical trial regime. And lastly, as the Company has internal manufacturing capabilities through its wholly owned subsidiary, Progenitor Cell Therapy (PCT), there are lower risks and uncertainties associated with manufacturing its cell therapy candidates.

Mr. Yorba and Dr. Smith discussed NeoStem's pipeline of proprietary cell therapy products, which continues to develop, most notably, NeoStem's completion of enrollment in its PreSERVE AMI Phase 2 clinical trial in December 2013, investigating the Company's most advanced product candidate, AMR-001, in preserving heart function after a severe heart attack. Data read out is expected in Q3 2014, and the Company is also exploring AMR-001 for chronic heart failure and traumatic brain injury. NeoStem also continues to advance its T regulatory cell program with the goal of developing treatments for immune modulated diseases such as type 1 diabetes, and inflammatory conditions such as steroid resistant asthma. Finally, NeoStem continues to develop its very small embryonic-like stem cell (VSEL™ Technology) platform in preclinical models with the goal of advancing into early clinical studies to explore the therapeutic potential of VSEL™ Technology in indications such as bone repair, healing complex skin and soft tissue wounds, and age-related macular degeneration.

In 2013, for the second year in a row, NeoStem was named the number one fastest growing company and number eleven nationally on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Deloitte looks at revenue and growth over a five year growth period as a benchmark. When Mr. Yorba asked Dr. Smith about winning this award, she noted that the Company was really proud to have won this award and to be in the company of such highly esteemed peer companies that were also in the running for the award.

Mr. Yorba and Dr. Smith also discussed NeoStem's unique model of growth. Instead of simply building the Company organically, NeoStem has grown through a series of acquisitions, and as such has become one of the fastest growing companies in its sector. NeoStem has completed five M&A transactions, one divestiture, and raised over 180 million dollars, enabling it to bring in key assets. As Dr. Smith explained, growing the Company in this manner has allowed NeoStem to acquire great talent, and the assets to potentially lead the industry. Speaking of NeoStem's revenue-generating operations through PCT, Dr. Smith said, "I think having the manufacturing is a real edge for us because we can generate revenues from the industry, we can lower the cost of goods, we can focus on things that the industry needs as a whole, and not only does it benefit our clients, but it benefits our internal development. We've created a very unique model that seems to be exciting to Wall Street and investors."

To hear the entire Clear Channel interview, click on the archive stream links below.

Interview Archive Segment 1 (9min, 37sec):
http://www.yorbamedia.com/images/stories/audio/TN021214SEG1.mp3

Interview Archive Segment 2 (10min, 41sec):
http://www.yorbamedia.com/images/stories/audio/TN021214SEG2.mp3  

Network: Clear Channel
Show: The Traders Network
Station: DFW 1190 AM KFXR
Host: Michael Yorba

Mr. Yorba remarked, "We give NeoStem two thumbs up and expect to see big things from Dr. Robin Smith in the near future. Exciting times and an exciting company." 

About Clear Channel: Clear Channel Media and Entertainment's more than 840 radio stations offer programming nationwide. Individual station brands connect with diverse audiences in local markets across the country reaching more than 112 million listeners. www.clearchannel.com.

About Michael Yorba: Michael Yorba -- featured host of Clear Channel's DFW 1190 AM in Dallas-Ft. Worth. For the past six years he has been integrally involved with the media industry in various capacities including building an IPTV Network, developing, producing and hosting a daily one hour talk show called Commodity Classics and then later The Traders Network, defined as an audience empowered interactive financial program that has been broadcast live on internet television and radio. His focus has been on derivative portfolio analysis for individual and corporate clients through the use of futures and futures options, managed funds, and Forex. www.yorbamedia.com

About NeoStem: NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts as well as efforts towards commercialization of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

A www.1800PublicRelations.com PR Event